✦ LIBER ✦

Valproate in the treatment of posttraumatic stress disorder: An open-label study

✍ Scribed by C. Otte; A. Yassouridis; K. Wiedemann; M. Kellner

Book ID: 119576290
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 124 KB
Volume: 12
Category: Article
ISSN: 0924-977X
DOI: 10.1016/s0924-977x(02)80533-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Divalproex in posttraumatic stress disor

Divalproex in posttraumatic stress disorder: An open-label clinical trial

✍ Ronald D. Clark; José M. Cañive; Lawrence A. Calais; Clifford R. Qualls; Vicente 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 355 KB

Valproate in the Treatment of Persistent

Valproate in the Treatment of Persistent Chronic Daily Headache. An Open Label Study

✍ Ninan T. Mathew; Sabiha Ali 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

Tiagabine for posttraumatic stress disor

Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment

✍ Kathryn M. Connor; Jonathan R. T. Davidson; Richard H. Weisler; Wei Zhang; Kuria 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 104 KB

An Open-Label Pilot Study of Divalproex

An Open-Label Pilot Study of Divalproex Sodium for Posttraumatic Stress Disorder Related to Childhood Abuse

✍ Joseph F Goldberg; Marylene Cloitre; Joyce E Whiteside; Hyemee Han 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 90 KB

Topiramate in post-traumatic stress diso

Topiramate in post-traumatic stress disorder — an open label study

✍ J. Berlant 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 336 KB

Short-term treatment of post-traumatic s

Short-term treatment of post-traumatic stress disorder with naltrexone: an open-label preliminary study

✍ Gad Lubin; Abraham Weizman; Mordechai Shmushkevitz; Avi Valevski 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB 👁 1 views

Eight patients (6 men and 2 women) with chronic post-traumatic stress disorder (PTSD) were treated with naltrexone 100-200 mg/day. Seven patients completed 2 weeks of treatment. A subtle and clinically insignificant improvement was noted in intrusive and hyperarousal symptoms (p < 0.05 for both), bu